Irbesartan Pensa

Irbesartan, the active ingredient in Irbesartan Pensa, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to lower high blood pressure and to protect kidney function in patients with diabetic nephropathy. It is indicated for adult patients and is available in the European market under strict manufacturing controls.

GNH USA supplies Irbesartan Pensa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch.

Irbesartan is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system.

Hypertension: reduction of elevated blood pressure in adult patients. Diabetic nephropathy: slowing of kidney function decline in patients with type 2 diabetes. Cardiovascular risk reduction: improvement of outcomes in patients with hypertension and associated cardiovascular risk factors.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate head pain. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat that may compromise breathing. - Hyperkalemia: elevated blood potassium levels that can affect heart rhythm. - Acute renal impairment: sudden decline in kidney function. - Hepatic injury: signs of liver dysfunction such as jaundice or elevated enzymes.

Before initiating therapy, consider the following precautions: - Monitor blood pressure: ensure adequate control and avoid hypotension. - Assess renal function: check serum creatinine and eGFR periodically. - Check serum potassium: avoid hyperkalemia, especially when combined with potassium‑sparing agents. - Use caution in severe hepatic impairment: dose adjustment may be required. - Avoid use during pregnancy unless clearly needed: potential fetal risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several drug classes. Manage these interactions as indicated.

Major Interactions (Avoid): - Aliskiren in patients with diabetes: combined use can increase renal risk. - Dual therapy with ACE inhibitors or other ARBs: may cause excessive potassium rise and renal dysfunction. - Potassium‑sparing diuretics (e.g., spironolactone): heightened risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring. - Lithium: increased lithium levels, monitor for toxicity. - Cyclosporine: may raise serum creatinine, watch renal function. - NSAIDs: can blunt antihypertensive effect and affect renal perfusion.